

## **EVOTEC RECEIVES SBTi APPROVAL FOR ITS NEAR-TERM EMISSIONS REDUCTION TARGETS**

▶ *EVOTEC'S SCOPE 1 AND 2 TARGET AMBITIONS HAVE BEEN VALIDATED BY THE SCIENCE BASED TARGETS INITIATIVE ("SBTi") AS BEING IN LINE WITH A 1.5°C TRAJECTORY*

### **Hamburg, Germany, 08 November 2023:**

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company's near-term emissions reduction targets have been approved by the Science Based Targets initiative ("SBTi"). Evotec's science-based near-term target ambitions are compliant with SBTi criteria and recommendations and consistent with levels required to meet the goals of the Paris Agreement. Further, the SBTi has classified Evotec's Scope 1 and 2 target ambitions as being in line with a 1.5°C trajectory.

Evotec is committed to:

1. reduce absolute Scope 1 and 2 GHG emissions by 50.4% by 2032 from a 2021 base year,
2. increase the annual sourcing of renewable electricity from 25% in the base year to 100% by 2026, and to continue active annual sourcing of 100% renewable electricity through 2030,
3. reduce Scope 3 GHG emissions from purchased goods and services as well as capital goods by 72% per million € value added by 2032 from a 2021 base year. Evotec also commits that 80% of its suppliers by emissions covering purchased goods and services and capital goods will have-science-based targets by 2027.

The SBTi defines and promotes best practice in science-based target setting and independently assesses and validates companies' targets to increase accountability and credibility of corporate climate action. Evotec's Management signed the pledge to the Science Based Targets initiative (SBTi) in December 2020, committing to set targets aligned with the goals of the Paris Agreement, and Evotec submitted targets to the SBTi in January 2023.

**For further information, please contact the Corporate Communications Team:**

*Hinnerk Rohwedder, Director of Global Corporate Communications, [hinnerk.rohwedder@evotec.com](mailto:hinnerk.rohwedder@evotec.com);*

*Gabriele Hansen, SVP Head of Global Corporate Communications, [gabriele.hansen@evotec.com](mailto:gabriele.hansen@evotec.com), [www.evotec.com](http://www.evotec.com)*

**Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented:** “We are proud that Evotec has been recognised for taking proactive steps to reduce its greenhouse gas emissions by the Science Based Targets initiative. We strongly believe that we can create a healthier and more sustainable future together with our partners. SBTi’s approval of our near-term targets reflects our commitment to transparency, accountability, and meaningful climate action aligned with science.”

More information about Evotec’s efforts to reduce greenhouse gas emissions can be found in the Company’s Sustainability Report on [www.evotec.com/financial-reports](http://www.evotec.com/financial-reports).

### **About Science Based Targets initiative**

The Science Based Targets initiative (“SBTi”) drives ambitious climate action in the private sector by enabling organisations to set science-based emissions reduction targets. The SBTi is a partnership between CDP, the United Nations Global Compact, World Resources Institute (“WRI”) and the World Wide Fund for Nature (“WWF”). Science-based targets provide companies with a clearly defined path for companies to reduce greenhouse gas (“GHG”) emissions in line with the Paris Agreement goals.

#### *ABOUT EVOTEC SE*

*Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to [www.evotec.com](http://www.evotec.com) and follow us on X/Twitter [@Evotec](https://twitter.com/Evotec) and [LinkedIn](https://www.linkedin.com/company/evotec).*

#### *FORWARD-LOOKING STATEMENTS*

*This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.*